Study of glumetinib plus nab-docetaxel for advanced stomach cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced stomach cancer or another solid tumor that has spread.
- Your tumor must have a change in the MET gene (overexpression or amplification) confirmed by a central lab.
- You cannot have received prior treatment with a MET-targeted drug or docetaxel.
- You must be in fairly good health (ECOG score 0 or 1) and expected to live at least 3 more months.
- You cannot have untreated or worsening brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
This trial tests a combination of a targeted drug (Glumetinib) and chemotherapy (nab-docetaxel) against chemotherapy alone for people with advanced non-small cell lung cancer that has a high level of a protein called MET. It may offer a new option after standard immunotherapy and platinum chemo have stopped working.
This trial is testing a new form of the chemotherapy drug docetaxel (called albumin-bound docetaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this version of the drug works better or has fewer side effects.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests whether tepotinib combined with paclitaxel can treat stomach or gastroesophageal (GEJ) cancer that has spread and has specific MET gene changes. It may help by blocking the MET pathway that can drive tumor growth after standard chemotherapy.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Hear when a new Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.